Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Novartis AG | Fabhalta (iptacopan) - (APPLAUSE-IgAN) | IgA nephropathy (IgAN) | Phase 3 | Ongoing | Oral | Immunology |
| Novartis AG | Pluvicto (lutetium (177Lu) vipivotide tetraxetan) - (PSMAddition) | End-stage prostate cancer | Phase 3 | Intravenous | Oncology | |
| Novartis AG | Leqvio (inclisiran) - (V-DIFFERENCE) | Low-density lipoprotein cholesterol (LDL-C) | Phase 3 | Data Released | Subcutaneous injection | Cardiology |
| Novartis AG | Leqvio - (VICTORION-Mono China) | Low or moderate ASCVD risk and elevated LDL-C | Phase 3 | Ongoing | Subcutaneous | Cardiology |
| Novartis AG | Ianalumab - (VAYHIT2) | Primary immune thrombocytopenia (ITP) | Phase 3 | Data Released | Intravenous | Hematology |
| Novartis AG | Scemblix (asciminib) - (ASC4START) | Newly diagnosed Ph+ CML-CP | Phase 3 | Data Released | Oral | Oncology |
| Novartis AG | Cosentyx - (GCAptAIN) | Newly diagnosed or relapsing giant cell arteritis (GCA) | Phase 3 | Data Released | Subcutaneous | Immunology |
| Novartis AG | Fabhalta - (APPULSE-PNH) | Paroxysmal nocturnal hemoglobinuria (PNH) | Phase 3 | Data Released | Intravenous | Hematology |
